FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...

It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men living in rural areas compared to their ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...

What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...

MyMichigan Medical Center Sault has begun offering PSMA PET scans, providing men in the eastern Upper Peninsula with an advanced imaging tool to detect prostate cancer.

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...